Decitabine For Injection

Decitabine is a hypomethylating agent, a type of targeted chemotherapy that works by helping switch back on genes that control healthy blood cell maturation. In many patients with myelodysplastic syndromes (MDS), these genes have been silenced, leading to abnormal and poorly functioning blood cells. By reversing this process, Decitabine helps the bone marrow produce healthier, more mature cells over time. It is approved for the treatment of MDS, including both previously treated and untreated cases across several subtypes. It is also used in the management of acute myeloid leukemia (AML), particularly in older adults or those who may not be candidates for intensive chemotherapy. Administered as an intravenous infusion in cycles under the care of an experienced hematology-oncology team, it offers a structured and manageable treatment schedule. Many patients experience improved blood counts, reduced need for transfusions, and better overall quality of life during therapy. Its gentler approach compared to intensive chemotherapy makes it a valuable option for patients who may not tolerate stronger regimens. Regular blood tests and clinic visits help care teams monitor response and adjust treatment as needed. With its established role in hematologic cancer care, Decitabine continues to offer meaningful hope and improved disease control for many patients.